NEW YORK (GenomeWeb News) — IO Informatics has formed a working group with members of the life science research and business communities that aims to develop semantic applications that may be used to generate hypotheses from translational research data, the company said Thursday.
IO Informatics said the goal of the working group is to develop the company’s Sentient software to “refine and deliver methods” for qualifying biomarkers and developing hypotheses about diseases and treatments.
“Semantic technologies have come a long way since their inception and we feel the formation of the working group will be a welcome progression to this scientific area for both us and the scientific research community as a whole,” Pat Hurban, director of technology development at Cogenics, said.
CEO Robert Stanley said the “mandate of the working group is to identify challenges and areas for focus and to work toward providing solutions to critical issues.”
Stanley said current members in the group include Hurban and Allan Higgins, also of Cogenics; Jones Almeida, a bioinformatics professor at MD Anderson Cancer Center; and Ted Slater, a senior manager at Pfizer’s Indications and Pathways Center of Emphasis.
The company will soon have two new members from big pharma and one from another center of excellence joining the working group, according to Erich Gombocz, IO’s chief scientific officer.